Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 466 participants.

Also called NCT04263922

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 466 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04263922
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04263922. Randomized; double masking; primary purpose treatment. Start 2020-06-30 (actual); primary completion 2025-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
Huaiqihuang granules
Intervention (Drug)
Valsartan capsule
Lead sponsor
The First Affiliated Hospital of Dalian Medical University (class: other)
Collaborator
Huazhong University of Science and Technology (class: other)
Collaborator
LinkDoc Technology (Beijing) Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04263922
Content hash
8a21e48c6e4641e0baed00c102469cd3b7093354178158a8f51eb28f30303b4a